Title:
COMPOUND AS INHIBITOR FOR SUMO ACTIVATING ENZYME
Document Type and Number:
WIPO Patent Application WO/2024/067676
Kind Code:
A1
Abstract:
Provided are a compound represented by general formula (1), a preparation method therefor, and use of the compound represented by general formula (1) and isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates thereof as SAE inhibitors. The compound and isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates thereof can be used for preparing a drug for treating or preventing diseases related to an SAE protein.
Inventors:
XIE YULI (CN)
WU YINGMING (CN)
QIAN LIHUI (CN)
WU YINGMING (CN)
QIAN LIHUI (CN)
Application Number:
PCT/CN2023/121932
Publication Date:
April 04, 2024
Filing Date:
September 27, 2023
Export Citation:
Assignee:
WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN)
International Classes:
C07D495/10; A61K31/381; A61K31/506; A61P35/00; C07D237/24
Foreign References:
| CN106999479A | 2017-08-01 | |||
| CN105492429A | 2016-04-13 | |||
| CN103923021A | 2014-07-16 | |||
| CN101379061A | 2009-03-04 |
Other References:
LANGSTON STEVEN P., GROSSMAN STEPHEN, ENGLAND DYLAN, AFROZE ROUSHAN, BENCE NEIL, BOWMAN DOUGLAS, BUMP NANCY, CHAU RYAN, CHUANG BEI: "Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 64, no. 5, 11 March 2021 (2021-03-11), US , pages 2501 - 2520, XP055897008, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.0c01491
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF: